Clinical Trial Update: Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs [Phase 2]

View source ↗

Summary

A Phase 2 trial conducted by GlaxoSmithKline evaluated four formulations of a meningococcal ACWY conjugate vaccine given as a single dose to healthy adolescents…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Meningococcal ACWY Conjugate Vaccine (Meningococcal conjugate vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED